These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 35865092)

  • 1. Why 90% of clinical drug development fails and how to improve it?
    Sun D; Gao W; Hu H; Zhou S
    Acta Pharm Sin B; 2022 Jul; 12(7):3049-3062. PubMed ID: 35865092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure‒tissue exposure/selectivity relationship (STR) correlates with clinical efficacy/safety.
    Gao W; Hu H; Dai L; He M; Yuan H; Zhang H; Liao J; Wen B; Li Y; Palmisano M; Traore MDM; Zhou S; Sun D
    Acta Pharm Sin B; 2022 May; 12(5):2462-2478. PubMed ID: 35646532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of an exceptionally potent and selective class of fatty acid amide hydrolase inhibitors enlisting proteome-wide selectivity screening: concurrent optimization of enzyme inhibitor potency and selectivity.
    Leung D; Du W; Hardouin C; Cheng H; Hwang I; Cravatt BF; Boger DL
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1423-8. PubMed ID: 15713400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
    Meanwell NA
    Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
    Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
    Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progressing preclinical drug candidates: strategies on preclinical safety studies and the quest for adequate exposure.
    Higgins J; Cartwright ME; Templeton AC
    Drug Discov Today; 2012 Aug; 17(15-16):828-36. PubMed ID: 22546604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal dose selection accounting for patient subpopulations in a randomized Phase II trial to maximize the success probability of a subsequent Phase III trial.
    Takahashi F; Morita S
    J Biopharm Stat; 2018; 28(5):870-883. PubMed ID: 29420118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probing the links between in vitro potency, ADMET and physicochemical parameters.
    Gleeson MP; Hersey A; Montanari D; Overington J
    Nat Rev Drug Discov; 2011 Mar; 10(3):197-208. PubMed ID: 21358739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The history of the development and changes of quinolone antibacterial agents].
    Takahashi H; Hayakawa I; Akimoto T
    Yakushigaku Zasshi; 2003; 38(2):161-79. PubMed ID: 15143768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data.
    Reboul FL
    Hematol Oncol Clin North Am; 2004 Feb; 18(1):41-53. PubMed ID: 15005280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimization of physicochemical properties is a strategy to improve drug-likeness associated with activity: Novel active and selective compounds against Trypanosoma cruzi.
    Varela MT; Amaral M; Romanelli MM; de Castro Levatti EV; Tempone AG; Fernandes JPS
    Eur J Pharm Sci; 2022 Apr; 171():106114. PubMed ID: 34986415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety assessment considerations and strategies for targeted small molecule cancer therapeutics in drug discovery.
    Westhouse RA
    Toxicol Pathol; 2010 Jan; 38(1):165-8. PubMed ID: 19907054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Target and Tissue Selectivity Prediction by Integrated Mechanistic Pharmacokinetic-Target Binding and Quantitative Structure Activity Modeling.
    Vlot AHC; de Witte WEA; Danhof M; van der Graaf PH; van Westen GJP; de Lange ECM
    AAPS J; 2017 Dec; 20(1):11. PubMed ID: 29204742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics in Drug Discovery: An Exposure-Centred Approach to Optimising and Predicting Drug Efficacy and Safety.
    Reichel A; Lienau P
    Handb Exp Pharmacol; 2016; 232():235-60. PubMed ID: 26330260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ten years of dengue drug discovery: progress and prospects.
    Lim SP; Wang QY; Noble CG; Chen YL; Dong H; Zou B; Yokokawa F; Nilar S; Smith P; Beer D; Lescar J; Shi PY
    Antiviral Res; 2013 Nov; 100(2):500-19. PubMed ID: 24076358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formulation approaches in mitigating toxicity of orally administrated drugs.
    Kadiyala I; Tan E
    Pharm Dev Technol; 2013; 18(2):305-12. PubMed ID: 23317423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug Repurposing for Paracoccidioidomycosis Through a Computational Chemogenomics Framework.
    de Oliveira AA; Neves BJ; Silva LDC; Soares CMA; Andrade CH; Pereira M
    Front Microbiol; 2019; 10():1301. PubMed ID: 31244810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of therapeutic strategies: a new method for balancing risk and benefit.
    Troche CJ; Paltiel AD; Makuch RW
    Value Health; 2000; 3(1):12-22. PubMed ID: 16464177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A medicinal chemistry perspective on structure-based drug design and development.
    Maddaford SP
    Methods Mol Biol; 2012; 841():351-81. PubMed ID: 22222460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.